propofol has been researched along with Respiratory Distress Syndrome in 32 studies
Propofol: An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS.
propofol : A phenol resulting from the formal substitution of the hydrogen at the 2 position of 1,3-diisopropylbenzene by a hydroxy group.
Respiratory Distress Syndrome: A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The incidence and risk factors for propofol-associated hypertriglyceridemia (HTG) in patients receiving extracorporeal membrane oxygenation (ECMO) have not been evaluated." | 8.31 | Propofol-Associated Hypertriglyceridemia in Adults With Acute Respiratory Distress Syndrome on Extracorporeal Membrane Oxygenation. ( Erkanli, A; Kim, H; Ohman, K; Parish, A; Rackley, CR; Schultheis, J; Stallworth, S, 2023) |
| "A higher-than-usual resistance to standard sedation regimens in COVID-19 patients suffering from acute respiratory distress syndrome (ARDS) has led to the frequent use of the second-line anaesthetic agent ketamine." | 8.12 | Long-term ketamine infusion-induced cholestatic liver injury in COVID-19-associated acute respiratory distress syndrome. ( Andermatt, R; Bartussek, J; Buehler, PK; Camen, G; David, S; Erlebach, R; Hofmaenner, DA; Jüngst, C; Müllhaupt, B; Schuepbach, RA; Wendel-Garcia, PD, 2022) |
| "The goal of this study was to confirm whether or not sevoflurane is more effective than propofol in ameliorating the inflammatory response in an animal model of acute respiratory distress syndrome." | 7.79 | Sevoflurane, but not propofol, reduces the lung inflammatory response and improves oxygenation in an acute respiratory distress syndrome model: a randomised laboratory study. ( Aguilar, G; Belda, FJ; Ferrando, C; Moreno, J; Piqueras, L; Soro, M, 2013) |
| "To explore whether propofol plays a protective role in kidney injury during acute respiratory distress syndrome (ARDS) by affecting the expression of Gq/11 protein." | 7.73 | [Influence of propofol on Gq/11 protein in kidney during acute respiratory distress syndrome]. ( Abasi, K; Jialili, A; Li, XJ; Zhang, L, 2006) |
| "Propofol is an antiinflammatory and immunosuppressive drug." | 5.33 | Attenuation of acute lung injury with propofol in endotoxemia. ( Mikawa, K; Nishina, K; Obara, H; Takao, Y, 2005) |
| "A higher-than-usual resistance to standard sedation regimens in COVID-19 patients suffering from acute respiratory distress syndrome (ARDS) has led to the frequent use of the second-line anaesthetic agent ketamine." | 4.12 | Long-term ketamine infusion-induced cholestatic liver injury in COVID-19-associated acute respiratory distress syndrome. ( Andermatt, R; Bartussek, J; Buehler, PK; Camen, G; David, S; Erlebach, R; Hofmaenner, DA; Jüngst, C; Müllhaupt, B; Schuepbach, RA; Wendel-Garcia, PD, 2022) |
| "The goal of this study was to confirm whether or not sevoflurane is more effective than propofol in ameliorating the inflammatory response in an animal model of acute respiratory distress syndrome." | 3.79 | Sevoflurane, but not propofol, reduces the lung inflammatory response and improves oxygenation in an acute respiratory distress syndrome model: a randomised laboratory study. ( Aguilar, G; Belda, FJ; Ferrando, C; Moreno, J; Piqueras, L; Soro, M, 2013) |
| "We conclude that the severity of remote lung injury was not different between sevoflurane and propofol anaesthesia in this porcine model of severe lower-body ischaemia and reperfusion injury." | 3.74 | Lung injury following thoracic aortic occlusion: comparison of sevoflurane and propofol anaesthesia. ( Annecke, T; Bittmann, I; Conzen, PF; Hilberath, JM; Kahr, S; Kemming, GI; Krombach, F; Kubitz, JC; Langer, K; Rehm, M, 2008) |
| "High-dose propofol infusion for sedation of patients in the intensive care unit can result in rhabdomyolysis, acute renal failure, metabolic acidosis, hyperkalemia, ventricular arrhythmia, hyperthermia, and death." | 3.73 | A lethal complication of propofol. ( Chavez, VM; Haake, RJ; Hayat, SA; Suen, HC, 2006) |
| "To explore whether propofol plays a protective role in kidney injury during acute respiratory distress syndrome (ARDS) by affecting the expression of Gq/11 protein." | 3.73 | [Influence of propofol on Gq/11 protein in kidney during acute respiratory distress syndrome]. ( Abasi, K; Jialili, A; Li, XJ; Zhang, L, 2006) |
| "In acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), recruitment manoeuvres (RMs) are used frequently." | 2.76 | Prolonged moderate pressure recruitment manoeuvre results in lower optimal positive end-expiratory pressure and plateau pressure. ( Lindgren, S; Lowhagen, K; Lundin, S; Odenstedt, H; Stenqvist, O, 2011) |
| "Propofol was administered by intermittent intravenous bolus titration by trained practice nurses under supervision of the gastroenterologist." | 2.73 | Propofol sedation in outpatient colonoscopy by trained practice nurses supervised by the gastroenterologist: a prospective evaluation of over 3000 cases. ( Sieg, A, 2007) |
| "Propofol was administered by continuous infusion at an initial rate of 5 microg/kg per min and titrated as needed." | 2.69 | Effects of propofol containing EDTA on mineral metabolism in medical ICU patients with pulmonary dysfunction. ( Abraham, E; Hall, JB; Papadakos, PJ; Tharratt, RS; Williams, GJ, 2000) |
| "Propofol was infused at 1." | 1.91 | Unusual case of propofol-related infusion syndrome complicating severe COVID-19 ARDS. ( Babu, VK; Garcia-Fernandez, A; Perez Del Nogal, G; Rojas, P, 2023) |
| "Propofol exposure may increase the risk of ICUAW in septic patients." | 1.46 | Propofol as a Risk Factor for ICU-Acquired Weakness in Septic Patients with Acute Respiratory Failure. ( Abdelmalik, PA; Rakocevic, G, 2017) |
| "The complications, including acute renal failure, disseminated intravascular coagulation, and acute respiratory distress syndrome were also treated without any obvious organ damage." | 1.39 | Continuous veno-venous hemofiltration for massive rhabdomyolysis after malignant hyperthermia: report of 2 cases. ( Fang, S; Jiang, H; Xu, H; Zhu, Y, 2013) |
| "Treatment with propofol abrogated or reversed the oleic acid-induced changes." | 1.35 | Protective effects of propofol on acute lung injury induced by oleic acid in conscious rats. ( Chen, HI; Hsieh, NK; Kao, SJ; Su, CF, 2008) |
| "Propofol is an antiinflammatory and immunosuppressive drug." | 1.33 | Attenuation of acute lung injury with propofol in endotoxemia. ( Mikawa, K; Nishina, K; Obara, H; Takao, Y, 2005) |
| "Our patient was newly diagnosed to have autoimmune hepatitis that may have predisposed her to toxicity from corticosteroids and neuromuscular-blocking agents, but she recovered her strength completely." | 1.33 | Critical care myopathy in a child. ( Newman, AJ; Singer, NG, 2005) |
| "The propofol of 10 mg/kg was administered intraperitoneally in the propofol group (60 rats) twice a day for four consecutive days one hour after the rats were intoxicated while the normal saline of the same amount as propofol in the propofol group was administered in the intoxication group (60 rats) one hour after the rats were intoxicated." | 1.33 | [Propofol protecting rats from paraquat induced lung injury]. ( Hu, JL; Huang, HM; Li, XH; Shi, HW; Su, JL; Tian, YP, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (9.38) | 18.2507 |
| 2000's | 17 (53.13) | 29.6817 |
| 2010's | 6 (18.75) | 24.3611 |
| 2020's | 6 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Cortellazzo Wiel, L | 1 |
| Monasta, L | 1 |
| Pascolo, P | 1 |
| Servidio, AG | 1 |
| Levantino, L | 1 |
| Fasoli, S | 1 |
| Saccari, A | 1 |
| Cozzi, G | 1 |
| Barbi, E | 1 |
| Wendel-Garcia, PD | 1 |
| Erlebach, R | 1 |
| Hofmaenner, DA | 1 |
| Camen, G | 1 |
| Schuepbach, RA | 1 |
| Jüngst, C | 1 |
| Müllhaupt, B | 1 |
| Bartussek, J | 1 |
| Buehler, PK | 1 |
| Andermatt, R | 1 |
| David, S | 1 |
| Babu, VK | 1 |
| Rojas, P | 1 |
| Perez Del Nogal, G | 1 |
| Garcia-Fernandez, A | 1 |
| Stallworth, S | 1 |
| Ohman, K | 1 |
| Schultheis, J | 1 |
| Parish, A | 1 |
| Erkanli, A | 1 |
| Kim, H | 1 |
| Rackley, CR | 1 |
| Guay, CS | 1 |
| Bean, CD | 1 |
| Kwon, O | 1 |
| Brown, EN | 1 |
| Payen, JF | 1 |
| Chanques, G | 1 |
| Futier, E | 1 |
| Velly, L | 1 |
| Jaber, S | 1 |
| Constantin, JM | 1 |
| Fang, S | 1 |
| Xu, H | 1 |
| Zhu, Y | 1 |
| Jiang, H | 1 |
| Ferrando, C | 1 |
| Aguilar, G | 1 |
| Piqueras, L | 1 |
| Soro, M | 1 |
| Moreno, J | 1 |
| Belda, FJ | 1 |
| Eikermann, M | 1 |
| Vidal Melo, MF | 1 |
| Abdelmalik, PA | 1 |
| Rakocevic, G | 1 |
| Haitsma, JJ | 1 |
| Lachmann, B | 1 |
| Papadakos, PJ | 2 |
| Lowhagen, K | 1 |
| Lindgren, S | 1 |
| Odenstedt, H | 1 |
| Stenqvist, O | 1 |
| Lundin, S | 1 |
| Clouzeau, B | 1 |
| Bui, HN | 1 |
| Guilhon, E | 1 |
| Grenouillet-Delacre, M | 1 |
| Leger, MS | 1 |
| Saghi, T | 1 |
| Pillot, J | 1 |
| Filloux, B | 1 |
| Coz, S | 1 |
| Boyer, A | 1 |
| Vargas, F | 1 |
| Gruson, D | 1 |
| Hilbert, G | 1 |
| Ziser, A | 1 |
| Strickland, RA | 1 |
| Murray, MJ | 1 |
| Gao, J | 2 |
| Zeng, BX | 1 |
| Zhou, LJ | 1 |
| Yuan, SY | 1 |
| Zeng, B | 1 |
| Zhou, L | 1 |
| Varpula, T | 1 |
| Valta, P | 1 |
| Niemi, R | 1 |
| Takkunen, O | 1 |
| Hynynen, M | 1 |
| Pettilä, VV | 1 |
| Takao, Y | 1 |
| Mikawa, K | 1 |
| Nishina, K | 1 |
| Obara, H | 1 |
| Kahn, JM | 1 |
| Andersson, L | 1 |
| Karir, V | 1 |
| Polissar, NL | 1 |
| Neff, MJ | 1 |
| Rubenfeld, GD | 1 |
| Newman, AJ | 1 |
| Singer, NG | 1 |
| Suen, HC | 1 |
| Haake, RJ | 1 |
| Chavez, VM | 1 |
| Hayat, SA | 1 |
| Shi, HW | 1 |
| Hu, JL | 1 |
| Tian, YP | 1 |
| Huang, HM | 1 |
| Li, XH | 1 |
| Su, JL | 1 |
| Jialili, A | 1 |
| Abasi, K | 1 |
| Zhang, L | 1 |
| Li, XJ | 1 |
| Chondrogiannis, KD | 1 |
| Siontis, GC | 1 |
| Koulouras, VP | 1 |
| Lekka, ME | 1 |
| Nakos, G | 1 |
| Sieg, A | 1 |
| Chen, HI | 1 |
| Hsieh, NK | 1 |
| Kao, SJ | 1 |
| Su, CF | 1 |
| Yu, HP | 1 |
| Lau, YT | 1 |
| Annecke, T | 1 |
| Kubitz, JC | 1 |
| Langer, K | 1 |
| Hilberath, JM | 1 |
| Kahr, S | 1 |
| Krombach, F | 1 |
| Bittmann, I | 1 |
| Rehm, M | 1 |
| Kemming, GI | 1 |
| Conzen, PF | 1 |
| el-Ebiary, M | 1 |
| Torres, A | 1 |
| Ramirez, J | 1 |
| Xaubet, A | 1 |
| Rodriguez-Roisin, R | 1 |
| Valente, JF | 1 |
| Anderson, GL | 1 |
| Branson, RD | 1 |
| Johnson, DJ | 1 |
| Davis, K | 1 |
| Porembka, DT | 1 |
| Cammarano, WB | 1 |
| Pittet, JF | 1 |
| Weitz, S | 1 |
| Schlobohm, RM | 1 |
| Marks, JD | 1 |
| Abraham, E | 1 |
| Tharratt, RS | 1 |
| Hall, JB | 1 |
| Williams, GJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| AnaConDa-therapy in COVID-19 Patients[NCT05586126] | 42 participants (Actual) | Observational | 2020-10-01 | Terminated (stopped due to Concerns about possible association between drug and increased ICU mortality) | |||
| Volatile Anesthetic Pharmacokinetics During Extracorporeal Membrane[NCT05680545] | 10 participants (Anticipated) | Interventional | 2024-07-01 | Not yet recruiting | |||
| A Randomized Pilot Clinical Trial of the Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction of Sevoflurane in Patient's Whit ARDS Secondary to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2)[NCT04998253] | Early Phase 1 | 24 participants (Actual) | Interventional | 2020-10-01 | Completed | ||
| Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)[NCT00000579] | Phase 3 | 0 participants | Interventional | 1994-09-30 | Completed | ||
| Assessment of Analgesics and Sedatives in Mechanically Ventilated Patients With COVID-19[NCT05336656] | 353 participants (Actual) | Observational | 2022-01-01 | Completed | |||
| Investigation of Changes in the Levels of Exhaled NO and Eosinophil Blood Count in Patients Undergoing Thyroidectomy by Two Different Methods of General Anesthesia Maintenance[NCT02065635] | 60 participants (Actual) | Interventional | 2014-05-31 | Completed | |||
| Opioids Withdrawal Syndrome in Critically Ill Patients: a Multicenter Prospective Cohort Study[NCT02318290] | 54 participants (Actual) | Observational | 2015-01-31 | Completed | |||
| Opioid Withdrawal Symptoms in Critically Ill Patients[NCT03374722] | 55 participants (Actual) | Observational | 2018-01-01 | Completed | |||
| Signs and Symptoms of Opioid-associated Iatrogenic Withdrawal in Critically Ill Adults[NCT03435614] | 29 participants (Actual) | Observational | 2018-02-26 | Completed | |||
| Assessing Current Analgesia and Sedation Weaning Practices in Adult Critically Ill Patients[NCT04422808] | 2,437 participants (Actual) | Observational | 2021-06-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Percentage of daily assessments associated with each of the following signs and symptoms experienced by patients with and without OIWS (Restlessness (Richmond Agitation-Sedation scale = 1), Agitation (RASS > 1), Anxiety, Hallucinations, Insomnia/sleep disturbance (< 4 hours of continuous sleep), Mydriasis (Pupil diameter > 2 mm) and systolic blood pressure (SBP) > 140 mmHg. These assessments were performed once daily.~Note that for the group of patients experiencing IWS, the data on signs and symptoms are limited to the assessment on the day that patients experienced OIWS.~The signs and symptoms presented (Restlessness; Agitation; Anxiety, Hallucinations, Insomnia/sleep disturbance; mydriasis; SBP > 140) were selected based on a > 15 % absolute difference between both groups which was judged to be clinically significant." (NCT03435614)
Timeframe: From first day of opioid dose reduction until transfer out of Intensive care unit (ICU) or a maximum of 14 days, including one further assessment post-ICU transfer
| Intervention | percentage of assessments (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Restlessness (RASS = 1) | Agitation (RASS > 1) | Anxiety | Hallucinations | Insomnia/Sleep disturbance (< 4 hours of continuous sleep) | Mydriasis (pupil size > 2mm) | Systolic Blood Pressure (SBP) > 140 mmHg | |
| IWS Negative | 13.6 | 4.9 | 30.6 | 11.2 | 21.4 | 77.8 | 53 |
| IWS Positive | 28.6 | 28.6 | 57.1 | 28.6 | 66.7 | 100 | 85.7 |
1 review available for propofol and Respiratory Distress Syndrome
| Article | Year |
|---|---|
Sedation for critically ill patients with COVID-19: Which specificities? One size does not fit all.
Topics: Analgesics, Opioid; Betacoronavirus; Coronavirus Infections; COVID-19; Critical Illness; Deep Sedati | 2020 |
5 trials available for propofol and Respiratory Distress Syndrome
| Article | Year |
|---|---|
Prolonged moderate pressure recruitment manoeuvre results in lower optimal positive end-expiratory pressure and plateau pressure.
Topics: Acute Lung Injury; Aged; Anesthetics, Intravenous; Cardiac Output; Cross-Over Studies; Electric Impe | 2011 |
Airway pressure release ventilation as a primary ventilatory mode in acute respiratory distress syndrome.
Topics: Adult; Anesthetics, Intravenous; Blood Pressure; Cardiac Output; Continuous Positive Airway Pressure | 2004 |
Low tidal volume ventilation does not increase sedation use in patients with acute lung injury.
Topics: Adult; Analgesics, Opioid; Benzodiazepines; Dose-Response Relationship, Drug; Female; Humans; Hypnot | 2005 |
Low tidal volume ventilation does not increase sedation use in patients with acute lung injury.
Topics: Adult; Analgesics, Opioid; Benzodiazepines; Dose-Response Relationship, Drug; Female; Humans; Hypnot | 2005 |
Low tidal volume ventilation does not increase sedation use in patients with acute lung injury.
Topics: Adult; Analgesics, Opioid; Benzodiazepines; Dose-Response Relationship, Drug; Female; Humans; Hypnot | 2005 |
Low tidal volume ventilation does not increase sedation use in patients with acute lung injury.
Topics: Adult; Analgesics, Opioid; Benzodiazepines; Dose-Response Relationship, Drug; Female; Humans; Hypnot | 2005 |
Propofol sedation in outpatient colonoscopy by trained practice nurses supervised by the gastroenterologist: a prospective evaluation of over 3000 cases.
Topics: Ambulatory Care; Cohort Studies; Colonoscopy; Female; Gastroenterology; Germany; Humans; Hypnotics a | 2007 |
Effects of propofol containing EDTA on mineral metabolism in medical ICU patients with pulmonary dysfunction.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anesthetics, Intravenous; Calcium; Chelating A | 2000 |
26 other studies available for propofol and Respiratory Distress Syndrome
| Article | Year |
|---|---|
Recovery characteristics and parental satisfaction in pediatric procedural sedation.
Topics: Child; Conscious Sedation; Dexmedetomidine; Hallucinations; Humans; Hypnotics and Sedatives; Ketamin | 2022 |
Long-term ketamine infusion-induced cholestatic liver injury in COVID-19-associated acute respiratory distress syndrome.
Topics: Bilirubin; COVID-19; Critical Illness; Humans; Hypnotics and Sedatives; Ketamine; Liver; Propofol; R | 2022 |
Unusual case of propofol-related infusion syndrome complicating severe COVID-19 ARDS.
Topics: Acidosis; Aged; COVID-19; Humans; Hyperlipidemias; Hypertriglyceridemia; Male; Propofol; Propofol In | 2023 |
Propofol-Associated Hypertriglyceridemia in Adults With Acute Respiratory Distress Syndrome on Extracorporeal Membrane Oxygenation.
Topics: Adult; Cohort Studies; Extracorporeal Membrane Oxygenation; Humans; Hypertriglyceridemia; Propofol; | 2023 |
Recovery From Acute Respiratory Distress Syndrome Is Associated With Increasing Alpha Power in the Frontal Electroencephalogram During Propofol Sedation: A Case Report.
Topics: Adult; Anesthesia; Electroencephalography; Humans; Hypnotics and Sedatives; Male; Propofol; Respirat | 2023 |
Continuous veno-venous hemofiltration for massive rhabdomyolysis after malignant hyperthermia: report of 2 cases.
Topics: Acute Kidney Injury; Adolescent; Adult; Anesthesia, Dental; Anesthesia, General; Anesthetics, Intrav | 2013 |
Sevoflurane, but not propofol, reduces the lung inflammatory response and improves oxygenation in an acute respiratory distress syndrome model: a randomised laboratory study.
Topics: Anesthesia; Anesthetics, Inhalation; Animals; Cell Membrane Permeability; Disease Models, Animal; He | 2013 |
Sevoflurane, but not propofol, reduces the lung inflammatory response and improves oxygenation in an acute respiratory distress syndrome model: a randomised laboratory study.
Topics: Anesthesia; Anesthetics, Inhalation; Animals; Cell Membrane Permeability; Disease Models, Animal; He | 2013 |
Sevoflurane, but not propofol, reduces the lung inflammatory response and improves oxygenation in an acute respiratory distress syndrome model: a randomised laboratory study.
Topics: Anesthesia; Anesthetics, Inhalation; Animals; Cell Membrane Permeability; Disease Models, Animal; He | 2013 |
Sevoflurane, but not propofol, reduces the lung inflammatory response and improves oxygenation in an acute respiratory distress syndrome model: a randomised laboratory study.
Topics: Anesthesia; Anesthetics, Inhalation; Animals; Cell Membrane Permeability; Disease Models, Animal; He | 2013 |
Sevoflurane, but not propofol, reduces the lung inflammatory response and improves oxygenation in an acute respiratory distress syndrome model: a randomised laboratory study.
Topics: Anesthesia; Anesthetics, Inhalation; Animals; Cell Membrane Permeability; Disease Models, Animal; He | 2013 |
Sevoflurane, but not propofol, reduces the lung inflammatory response and improves oxygenation in an acute respiratory distress syndrome model: a randomised laboratory study.
Topics: Anesthesia; Anesthetics, Inhalation; Animals; Cell Membrane Permeability; Disease Models, Animal; He | 2013 |
Sevoflurane, but not propofol, reduces the lung inflammatory response and improves oxygenation in an acute respiratory distress syndrome model: a randomised laboratory study.
Topics: Anesthesia; Anesthetics, Inhalation; Animals; Cell Membrane Permeability; Disease Models, Animal; He | 2013 |
Sevoflurane, but not propofol, reduces the lung inflammatory response and improves oxygenation in an acute respiratory distress syndrome model: a randomised laboratory study.
Topics: Anesthesia; Anesthetics, Inhalation; Animals; Cell Membrane Permeability; Disease Models, Animal; He | 2013 |
Sevoflurane, but not propofol, reduces the lung inflammatory response and improves oxygenation in an acute respiratory distress syndrome model: a randomised laboratory study.
Topics: Anesthesia; Anesthetics, Inhalation; Animals; Cell Membrane Permeability; Disease Models, Animal; He | 2013 |
Therapeutic range of spontaneous breathing during mechanical ventilation.
Topics: Anesthetics, Intravenous; Animals; Diaphragm; Lung Injury; Male; Muscular Atrophy; Propofol; Respira | 2014 |
Propofol as a Risk Factor for ICU-Acquired Weakness in Septic Patients with Acute Respiratory Failure.
Topics: Adult; Aged; Cohort Studies; Critical Illness; Electronic Health Records; Female; Humans; Hypnotics | 2017 |
Additives in intravenous anesthesia modulate pulmonary inflammation in a model of LPS-induced respiratory distress.
Topics: Acute Lung Injury; Adjuvants, Anesthesia; Anesthesia, Intravenous; Animals; Bronchoalveolar Lavage F | 2009 |
Fiberoptic bronchoscopy under noninvasive ventilation and propofol target-controlled infusion in hypoxemic patients.
Topics: Adult; Aged; Anesthetics, Intravenous; Bronchoalveolar Lavage; Bronchoscopy; Drug Delivery Systems; | 2011 |
Propofol does not induce pulmonary dysfunction in stressed endotoxic pigs receiving Intralipid.
Topics: Animals; Dose-Response Relationship, Drug; Fat Emulsions, Intravenous; Hemodynamics; Lung; Male; Pro | 2003 |
Protective effects of early treatment with propofol on endotoxin-induced acute lung injury in rats.
Topics: Anesthetics, Intravenous; Animals; Blotting, Western; Bronchoalveolar Lavage Fluid; Drug Administrat | 2004 |
The protective effects of early treatment with propofol on endotoxin-induced acute lung injury in rats.
Topics: Analysis of Variance; Anesthetics, Intravenous; Animals; Blotting, Western; Hemodynamics; Lipopolysa | 2003 |
Attenuation of acute lung injury with propofol in endotoxemia.
Topics: Animals; Blood Pressure; Endotoxemia; Lung; Male; Nitric Oxide Synthase; Peroxynitrous Acid; Propofo | 2005 |
Critical care myopathy in a child.
Topics: Adolescent; Adrenal Cortex Hormones; Creatine Kinase; Critical Care; Female; Hepatitis, Autoimmune; | 2005 |
A lethal complication of propofol.
Topics: Acidosis; Acute Kidney Injury; Adult; Anesthetics, Intravenous; Creatine Kinase; Dose-Response Relat | 2006 |
[Propofol protecting rats from paraquat induced lung injury].
Topics: Animals; Bronchoalveolar Lavage Fluid; Hydroxyproline; Lung; Male; Malondialdehyde; Paraquat; Propof | 2006 |
[Influence of propofol on Gq/11 protein in kidney during acute respiratory distress syndrome].
Topics: Animals; Disease Models, Animal; GTP-Binding Protein alpha Subunits, Gq-G11; Kidney; Male; Propofol; | 2006 |
Acute lung injury probably associated with infusion of propofol emulsion.
Topics: Cerebral Hemorrhage; Critical Care; Female; Humans; Hypnotics and Sedatives; Middle Aged; Propofol; | 2007 |
Protective effects of propofol on acute lung injury induced by oleic acid in conscious rats.
Topics: Animals; Disease Models, Animal; Hemodynamics; Hypnotics and Sedatives; Male; Oleic Acid; Propofol; | 2008 |
Since when did sedatives start to save lives?
Topics: Animals; Cytokines; Humans; Hypnotics and Sedatives; Propofol; Respiratory Distress Syndrome | 2008 |
Lung injury following thoracic aortic occlusion: comparison of sevoflurane and propofol anaesthesia.
Topics: Anesthesia; Anesthetics, Inhalation; Anesthetics, Intravenous; Animals; Aorta, Thoracic; Arterial Oc | 2008 |
Lipid deposition during the long-term infusion of propofol.
Topics: Aged; Embolism, Fat; Enteral Nutrition; Fatal Outcome; Humans; Hypnotics and Sedatives; Infusions, I | 1995 |
Disadvantages of prolonged propofol sedation in the critical care unit.
Topics: Adult; Critical Care; Female; Humans; Intensive Care Units; Postoperative Complications; Propofol; R | 1994 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |
Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.
Topics: Acute Disease; Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Benzodiazepines; Dose-Response | 1998 |